Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Burzynski Research Institute, Inc. (BZYR) - Financial and Strategic SWOT Analysis Review

VIEWS: 24 PAGES: 31

Burzynski Research Institute, Inc. (BZYR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Burzynski Research Institute, Inc. (BRI) is a research based biopharmaceutical co

More Info
  • pg 1
									              Burzynski Research Institute, Inc. (BZYR) - Financial and Strategic
                                  SWOT Analysis Review
        Reference Code: GDPH137119FSA                                                                                            Publication Date: JUN 2013

          9432 Katy Freeway                               Phone             +1 713 3355697                          Revenue          NA
          Houston, TX                                     Fax               +1 713 9350649                          Net Profit       -7.16 (million USD)
          77055                                           Website           www.burzynskiresearch.com               Employees        2
                                                                                                                                     Pharmaceuticals           &
          United States                                   Exchange          BZYR [Over The Counter]                 Industry
                                                                                                                                     Healthcare

       Company Overview
       Burzynski Research Institute, Inc. (BRI) is a research based biopharmaceutical company. It identifies, produces, markets,
       promots and sells medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic
       acids. The company offers these compounds under the trade name Antineoplastons. BRI's product portfolio consists of
       Antineoplastons, namely, A10 and AS2-1, being evaluated in Phase II clinical trial for the treatment of cancer. It also examines
       pharmacokinetics and pharmacodynamics of Antineoplastons in patients with neoplastic disease, and offers consulting services.
       BRI is headquartered in Houston, Texas, the US.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Burzynski Research Institute, Inc., SWOT Analysis
         Stanislaw R.         Burzynski, Chairman                                     Strengths                             Weaknesses
         M.D., Ph.D.
                                                                                      Research and Development              Partial Hold on Clinical Trials
         Patryk P. Goscianski                Director
         Barbara Burzynski, M.D.             Director                                 Agreements                            Limited Liquidity
         Carlton Hazlewood, Ph.D.            Director
         Gregory S. Burzynski, M.D.          Director                                 Opportunities                         Threats
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Orphan Drug Status                    Uncertain R&D Outcomes

       Share Data                                                                     Emerging Markets                      Regulatory Oversight
         Burzynski Research Institute, Inc.
        Share Price (USD) as on 14-Jun-                                  0.08        Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        2013
        EPS (USD)                                                       -0.05
        Market Cap (million USD)                                           11
        Enterprise Value (million USD)                                     11
        Shares Outstanding (million)                                     131
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Burzynski Research Institute, Inc. (BZYR) - Financial and Strategic                                                            Reference Code: GDPH137119FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                         Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 3
       Section 1 - About the Company.......................................................................................................................................................... 4
       Burzynski Research Institute, Inc. - Key Facts ................................................................................................................................... 4
       Burzynski Research Institute, Inc. - Key Employees .......................................................................................................................... 5
       Burzynski Research Institute, Inc. - Key Employee Biographies ........................................................................................................ 6
       Burzynski Research Institute, Inc. - Major Products and Services ..................................................................................................... 7
       Burzynski Research Institute, Inc. - Pharmaceutical Pipeline Products Data ..................................................................................... 8
          Burzynski Research Institute, Inc., Pipeline Products by Therapy Area ......................................................................................... 8
          Burzynski Research Institute, Inc., Pipeline Products by Development Phase ............................................................................... 9
       Burzynski Research Institute, Inc. - History ...................................................................................................................................... 11
       Burzynski Research Institute, Inc. - Company Statement................................................................................................................. 12
       Burzynski Research Institute, Inc. - Locations And Subsidiaries ...................................................................................................... 14
          Head Office ................................................................................................................................................................................... 14
          Other Locations & Subsidiaries ..................................................................................................................................................... 14
       Section 2 – Company Analysis ......................................................................................................................................................... 15
       Burzynski Research Institute, Inc. - Business Description ................................................................................................................ 15
       Burzynski Research Institute, Inc. - SWOT Analysis ........................................................................................................................ 16
          SWOT Analysis - Overview........................................................................................................................................................... 16
          Burzynski Research Institute, Inc. - Strengths .............................................................................................................................. 16
             Strength - Research and Development ..................................................................................................................................... 16
             Strength - Agreements .............................................................................................................................................................. 16
             Strength - Product Portfolio ....................................................................................................................................................... 16
          Burzynski Research Institute, Inc. - Weaknesses ......................................................................................................................... 16
             Weakness - Partial Hold on Clinical Trials................................................................................................................................. 16
             Weakness - Limited Liquidity..................................................................................................................................................... 17
          Burzynski Research Institute, Inc. - Opportunities ........................................................................................................................ 17
             Opportunity - Orphan Drug Status ............................................................................................................................................. 17
             Opportunity - Emerging Markets ............................................................................................................................................... 17
             Opportunity - Demographic Trends ...............
								
To top